<DOC>
	<DOCNO>NCT02244489</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , define maximum tolerate dose ( MTD ) momelotinib ( MMB ) combine capecitabine oxaliplatin adult relapsed/refractory metastatic pancreatic ductal adenocarcinoma .</brief_summary>
	<brief_title>Momelotinib Combined With Capecitabine Oxaliplatin Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Key Relapsed refractory metastatic pancreatic adenocarcinoma Received 1 prior chemotherapy regimen metastatic pancreatic ductal adenocarcinoma ( include neoadjuvant and/or adjuvant therapy ) Measurable disease per RECIST v1.1 Adequate organ function define Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 3 x upper limit normal ( ULN ) OR ≤ 5 x ULN liver metastases present ; total conjugate bilirubin ≤ 2 x ULN Absolute neutrophil count ( ANC ) ≥1500 cells/mm^3 , platelet ≥100,000 cells/mm^3 , hemoglobin ≥ 9.0 g/dL Creatinine clearance ( CrCl ) &gt; 50 ml/min calculate CockroftGault method Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Key Received 1 prior line chemotherapy metastatic pancreatic ductal adenocarcinoma Major surgery within 21 day first dose study drug Minor surgical procedure ( ) within 7 day enrollment yet recover prior minor surgery ( placement central venous access device , fine needle aspiration , endoscopic biliary stent ≥ 1 day enrollment acceptable ) Chemotherapy , immunotherapy , biologics , and/or investigational therapy within 21 day prior first dose study drug Known positive status HIV , chronic active acute viral hepatitis A , B , C infection , hepatitis B C carrier Known dihydropyrimidine dehydrogenase deficiency Peripheral neuropathy ≥ Grade 2 Any condition impairs gastrointestinal absorption drug Known suspect brain central nervous system metastases Diagnosis pancreatic islet neoplasm , acinar cell carcinoma , nonadenocarcinoma , adenocarcinoma originate biliary tree cystadenocarcinoma External biliary drain Documented myocardial infarction unstable/uncontrolled cardiac disease within 6 month enrollment Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>